REGEN-COV Phase 3 Trial Improves Survival in Patients Hospitalized with Severe COVID-19

June 17, 2021

A Phase 3 RECOVERY trial in the UK found that Regeneron’s REGEN-COV antibody treatment reduced the risk of death by 20% in patients who had not mounted their own immune response against COVID-19. In addition, among patients without their own immune response, the median duration of hospital stay was 4 days shorter in the REGEN-COV group, and there was a greater proportion of patients discharged by 28 days. Research has also shown that the treatment remains effective against the main variants of COVID-19 in the United States. 

REGEN-COV is a mix of two monoclonal antibodies known as casirivimab and imdevimab. These antibodies block the infection ability of SARS-COV-2, the virus that causes COVID-19.
The results of the RECOVERY trial demonstrate that REGEN-COV can “alter the course of COVID-19 infection from prevention to very early infection, all the way through to when patients are on a ventilator in the hospital.” Regeneron is working with the FDA to expand its current EUA to other populations such as hospitalized patients.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.